Liqun Zhou
About
Education & Training
- MS
- Yale University, Department of Immunobiology (2023)
- BS
- Tsinghua University, School of Life Sciences (2021)
- BM
- Tsinghua University, School of Economics and Management (2021)
Research
Publications
2023
Applications of CRISPR technology in cellular immunotherapy
Zhou X, Renauer P, Zhou L, Fang S, Chen S. Applications of CRISPR technology in cellular immunotherapy. Immunological Reviews 2023, 320: 199-216. PMID: 37449673, PMCID: PMC10787818, DOI: 10.1111/imr.13241.Peer-Reviewed Original ResearchPooled screening with next-generation gene editing tools
Liqun Zhou, Luojia Yang, Yanzhi Feng, Sidi Chen, Pooled screening with next-generation gene editing tools, Current Opinion in Biomedical Engineering, 2023, 100479, ISSN 2468-4511, https://doi.org/10.1016/j.cobme.2023.100479.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2022
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Mao T, Israelow B, Peña-Hernández MA, Suberi A, Zhou L, Luyten S, Reschke M, Dong H, Homer RJ, Saltzman WM, Iwasaki A. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 2022, 378: eabo2523. PMID: 36302057, PMCID: PMC9798903, DOI: 10.1126/science.abo2523.Peer-Reviewed Original ResearchConceptsRespiratory mucosaSystemic immunityLethal SARS-CoV-2 infectionAcute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemicSARS-CoV-2 infectionProtective mucosal immunityCross-reactive immunityT cell responsesCoronavirus 2 pandemicPrimary vaccinationParenteral vaccinesMucosal immunityVaccine strategiesRespiratory tractImmunoglobulin AMemory BImmune memoryPartial immunityCell responsesPoor immunityImmunitySpike proteinMucosaVaccineHeterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Fang Z, Peng L, Lucas C, Lin Q, Zhou L, Yang L, Feng Y, Ren P, Renauer PA, Monteiro VS, Hahn AM, Park JJ, Zhou X, Grubaugh N, Wilen C, Chen S. Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2. Cell Discovery 2022, 8: 69. PMID: 35853867, PMCID: PMC9295082, DOI: 10.1038/s41421-022-00435-w.Peer-Reviewed Original Research
2021
Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors
Liu Y, Liu G, Wang J, Zheng ZY, Jia L, Rui W, Huang D, Zhou ZX, Zhou L, Wu X, Lin S, Zhao X, Lin X. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Science Translational Medicine 2021, 13 PMID: 33762437, DOI: 10.1126/scitranslmed.abb5191.Peer-Reviewed Original ResearchConceptsCAR T cellsT cell receptorSolid tumorsChimeric antigen receptor T-cell therapyMultiple solid tumor modelsRefractory solid tumorsT-cell therapyDurable disease controlHigh response rateSynthetic T cell receptorsB-cell malignanciesHigh antigen sensitivitySolid tumor modelsAntigen recognition domainClinical benefitAntigen stimulationTumor relapseLimited efficacyAntigen sensitivityAntitumor effectsCell malignanciesResponse rateNotable toxicityTumor modelDisease control